中海油(00883.HK)綏中36-1/旅大5-2油田二次調整開發項目投產
中海油(00883.HK)今天(5日)宣布綏中36-1/旅大5-2油田二次調整開發項目投產。
該項目位於渤海遼東灣海域,平均水深約30米,主要生產設施包括新建2座中心處理平台和2座井口平台,計劃投產開發井118口,其中包括採油井81口,注水井37口。預計2025年將實現日產原油約30,300桶的高峰產量。
綏中36-1/旅大5-2油田二次調整開發項目是中國海上最大規模的二次開發調整項目。該項目秉承區域開發理念,為海上在產油氣田可持續開發提供了重要實踐參考。項目依託岸電開發,接入陸地綠色電力,穩步推進海洋油氣資源綠色低碳開發。
中海油擁有該項目100%的權益,並擔任作業者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.